New York , NY – March 30 , 2012- Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert and updated commentary from Josh Levine of the Levine MicroCap Newsletter, for Antares Pharma, Inc. (NYSE Amex: AIS).
In an Alert in mid December, Levine said the negative results on LibiGel’s Phase III trials for efficacy, which were issued by AIS partner BioSante Pharmaceuticals is “only a minor bump in the road for Antares. Today’s 30%-plus drop in AIS shares is an overreaction and the stock will rebound fully in time.” He concluded: “If you don’t own AIS, I recommend taking advantage of this anomaly. If you were considering adding to your current position, this is the time to move.”
Levine followed up on December 30 with this comment about AIS: “Antares has surged 30% in two weeks and is again trading above its 200-day moving average. The market quickly and correctly recognized that the LibiGel event does nothing to tarnish the company’s outlook, which has never been stronger.”
Today, the stock is trading at $3.30, up strongly from its sell off and low of $1.51 on December 15th. As the chart below illustrates, AIS shares have experienced some wild swings during the past year. Most notable was the plunge taken in December.
The shares traded as high as $3.45 on March 26, marking a gain of more than 100% in less than four months. AIS is now higher than its 2011 peak and trading at a level it hasn’t seen in a decade.
“When big inefficiencies in the market arise for small stocks, it presents great buying opportunities,” says Levine. “Understand that every situation is different and we must weigh a range of factors, starting with the news or event that caused the drop. In the case of AIS, it was abundantly clear the event was equivalent to a minor scratch, and the market’s overreaction was a gift for investors.”
About Josh Levine and Levine’s MicroCap Investor www.levinesmicrocapinvestor.com
Josh Levine has 25 years of senior-level experience in analyzing technology trends and investing in top-performing micro- and small-cap stocks.
About Antares Pharma, Inc. (NYSE Amex: AIS)
Antares Pharma focuses on self-injection pharmaceutical products and topical gel-based medicines. The Company’s subcutaneous and intramuscular injection technology platforms include VIBEX™ disposable pressure-assisted auto injectors, disposable multi-use pen injectors and Vision™ reusable needle-free injectors distributed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. In the injector area, Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH) and a partnership with Ferring that includes Zomacton® hGH. In the gel-based area, the Company’s FDA approved product is Anturol® gel, an oxybutynin ATD™ gel for the treatment of OAB (overactive bladder) which has been licensed to Watson Pharmaceuticals, Inc. for the U.S. and Canada. Antares’ partnership with BioSante includes LibiGel® transdermal testosterone gel in Phase 3 clinical development for the treatment of female sexual dysfunction (FSD), and Elestrin® estradiol gel indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and currently marketed in the U.S. Antares Pharma has two facilities in the U.S. The Parenteral Products Division located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted auto injector and pen injector systems. The Company’s corporate offices and Pharma Division are located in Ewing, New Jersey, where pharmaceutical products are developed utilizing both the Company’s transdermal systems and drug/device combination products.
Get biotech news and stock alerts
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure. BPAX compensates investorideas .com for news release dissemination and content creation. BC Residents and Investor Disclaimer : Effective September 15 2008 – all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 – Source – www.Investorideas.com